Exabis Library
Welcome to the e-CCO Library!
P491: Infectious risk of vedolizumab compared with other biological agents in the treatment of Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P491: INSPIRE: design and implementation aspects of a registry of complex perianal fistulas in Crohn’s disease patients treated with darvadstrocel
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P492 Use of bowel ultrasound to assess disease activity in Crohn’s disease patients after induction therapy with infliximab
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P492: A comparison of treatment effects for clinical, endoscopic and histological remission in ulcerative colitis clinical trials
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P492: Cumulative safety signal review confirmed the established safety profile of Asacol™† (mesalazine)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P492: Gender differences in patient’s perspectives for impact of inflammatory bowel disease on their life: An Online Korean Association for the Study of Intestinal Disease (KASID) survey
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P492: Influence of the interval of time between the first and the second anti-TNF in the response to treatment in patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P492: Perioperative complications have long-term effect on quality of life after restorative proctocolectomy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P492: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P492: The UC Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A prospective open label pilot study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P493 Segmental colectomy vs. extended colectomy for colonic Crohn’s disease: results from 112 consecutive patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P493: Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P493: Cost-effectiveness of venous thromboembolism prophylaxis after hospitalization in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P493: Efficacy of anti-TNF for internal fistula in Crohn's disease – results from a retrospective multicenter cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P493: Inflammatory sticturing Crohn’s diseases: results of medical treatment
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P493: Prevalence and risk factors for postoperative septic complications in Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P493: QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P493: The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P494 The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P494: A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM